Ae23-Translational and Integrative Oncology (Emerging)
Oncology / IBS-Ae23 / Emerging

The group carries out clinical, translational and integrative cancer research tasks with the main objective of facilitating the transition from basic research into clinical applications that benefit health. This translational medicine is aimed at amortizing the effort devoted to basic research for economic and medical benefit.
Research lines
- Translational Oncology
- Integrative Oncology
SANDRA REDONDO SANCHEZ
NOELIA FERNANDEZ GUERRERO
CRISTINA GOMEZ ALVAREZ
LAURA FIELDS
VANESSA GABRIELA JERVIZ GUIDE
ARACELI LOPEZ TEJADA
JOSE LUCAS BLAYA CANOVAS
JESUS CALAHORRA GARCIA-MORENO
CRISTINA PRIETO PRIETO
MARTA LEGEREN ALVAREZ
PATRICIA MARIA RODRIGUEZ GOMEZ
SATURN OF KINGS LARTATEGUI
SILVIA SEQUERO LOPEZ
TANIA GALLART ARAGON
CARLOS JOSE RODRIGUEZ GONZALEZ
MAIN SERGIO GRANADOS
CARMEN GRIÑAN LISON
ISABEL BLANCAS LOPEZ-BARAJAS
Early increase in tamoxifen dose in CYP2D6 poor metabolizer breast cancer patients and survival: A propensity score matching analysis
BREAST, 2023;
FI: 3,9; Q1
Discovery of a synthetic taiwaniaquinoid with potent in vitro and in vivo antitumor activity against breast cancer cells
BIOMEDICINE & PHARMACOTHERAPY, 2023;
FI: 7,5; Q1
TGFß Governs the Pleiotropic Activity of NDRG1 in Triple-Negative Breast Cancer Progression
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2023;
FI: 9,2; Q1
SEOM-GEICAM-SOLTI clinical guidelines in advanced breast cancer (2022) (May, 10.1007/s12094-023-03203-8, 2023)
CLINICAL & TRANSLATIONAL ONCOLOGY, 2023;
FI: 3,4; Q3
SEOM-GEICAM-SOLTI clinical guidelines in advanced breast cancer (2022)
CLINICAL & TRANSLATIONAL ONCOLOGY, 2023;
FI: 3,4; Q3
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study
ANNALS OF ONCOLOGY, 2022;
FI: 51,769; D1
EZH2 endorses cell plasticity to non-small cell lung cancer cells facilitating mesenchymal to epithelial transition and tumor colonization
ONCOGENE, 2022;
FI: 8,756; D1
Caffeine and Chlorogenic Acid Combination Attenuate Early-Stage Chemically Induced Colon Carcinogenesis in Mice: Involvement of oncomiR miR-21a-5p
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022;
FI: 6,208; Q1
Nanomedicine as a Promising Tool to Overcome Immune Escape in Breast Cancer
PHARMACEUTICS, 2022;
FI: 6,525; Q1
Acceleration of the DNA methylation clock among lynch syndrome-associated mutation carriers..
BMC MEDICAL GENOMICS, 2022;
FI: 3,622; Q2
Anti-CD44-Conjugated Olive Oil Liquid Nanocapsules for Targeting Pancreatic Cancer Stem Cells
BIOMACROMOLECULES, 2021;
FI: 6,988; D1
Antioxidants for the Treatment of Breast Cancer: Are We There Yet?.
ANTIOXIDANTS, 2021;
FI: 6,313; D1
Development of a Biomimetic Hydrogel Based on Predifferentiated Mesenchymal Stem-Cell-Derived ECM for Cartilage Tissue Engineering
ADVANCED HEALTHCARE MATERIALS, 2021;
FI: 9,933; D1
Impact of hydroxytyrosol on stroke: tracking therapeutic response on neuroinflammation and cerebrovascular parameters using PET-MR imaging and on functional outcomes
THERANOSTICS, 2021;
FI: 11,556; D1
Efficacy of naloxegol on symptoms and quality of life related to opioid-induced constipation in patients with cancer: a 3-month follow-up analysis
BMJ SUPPORTIVE & PALLIATIVE CARE, 2021;
FI: 3,568; Q2
Proof-of-concept for a new bimodal cancer nanovaccine to potentiate immunotherapy
Funder: AECC FOUNDATION
File number: IDEAS234367GRAN
Execution time: 01/12/2023 - 30/11/2025
IP: SERGIO GRANADOS MAIN
Hybrid nanoparticles of immune cells and cancer stem cells for targeted therapy of triple negative breast cancer.
Funder: PUBLIC FOUNDATION FOR BIOSANITARY RESEARCH OF ORIENTAL ANDALUCIA ALEJANDRO OTERO (FIBAO)
File number: INTRAIBS-2021-09
Execution time: 05/02/2022 - 04/02/2023
IP: CARMEN GRIÑAN LISON
Evaluation of response to advanced therapies and conventional treatments and use as CAR-T-Cell activator of tumor exosomes from metastatic breast cancer.
Funder: COUNCIL OF HEALTH AND FAMILIES
File number: PECART-0207-2020
Execution time: 28/10/2021 - 28/10/2023
IP: ISABEL BLANCAS LOPEZ-BARAJAS
Randomized, open-label phase III study to evaluate the efficacy and safety of giraredestrant in combination with phesgo compared to phesgo after induction treatment with phesgo + taxane in patients with locally advanced or metastatic breast cancer.
Financier: ROCHE FARMA, SA
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 15/11/2023 - 30/12/2032
IP: ISABEL BLANCAS LOPEZ-BARAJAS
Ambispective, non-interventional, multiple cohort study to evaluate the management of osimertinib treatment in patients with non-small cell lung cancer with EGFR mutations under real-life conditions in Spain. OSIREAL
Funder: ASTRAZENECA FARMACEUTICA ESPAÑA SA
Type of test: OBSERVATIONAL STUDY WITH MEDICATION
Execution time: 12/09/2023 - 30/07/2029
IP: SILVIA SEQUERO LOPEZ
Randomized controlled and single-blind clinical trial in women with breast cancer and axillary lymphadenectomy, to evaluate the effectiveness of Hemopatch® in reducing post-surgical serous drainage
Funder: TOLEDO ASSOCIATION OF BREAST SURGEONS
Type of test: CLINICAL RESEARCH WITH PROD. SANIT.
Execution time: 08/03/2023 - 30/12/2023
IP: TANIA GALLART ARAGON
Prospective analysis of biomarkers in patients with advanced or metastatic RH+/HER2- breast cancer treated with sacituzumab govitecan. ACROSS-TROP2 TRIAL
Funder: SOLTI
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 05/10/2023 - 30/08/2026
IP: ISABEL BLANCAS LOPEZ-BARAJAS
Phase III post-neoadjuvant study evaluating Sacituzumab Govitecan, an antibody conjugate, in patients with HER2-negative primary breast cancer at high risk of relapse after standard neoadjuvant treatment – SASCIA
Funder: GERMAN BREAST GBG FORSCHUNGSGESELLSCHAFT GMBH
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 01/03/2023 - 30/03/2029
IP: ISABEL BLANCAS LOPEZ-BARAJAS
Phase III, randomized, multicenter, placebo-controlled study to evaluate the efficacy and safety of the HER2/neu peptide GLSI-100 (GP2 + GM-CSF) in subjects with residual disease or high-risk HER2/neu-positive pCR after neoadjuvant treatment
Funder: GREENWICH LIFESCIENCES, INC.
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 18/09/2023 - 30/10/2028
IP: ISABEL BLANCAS LOPEZ-BARAJAS
Open-label, randomized, non-comparative Phase 2 study of ARV-471 or anastrozole in postmenopausal women with ER+/HER2– breast cancer in the neoadjuvant setting.TRIO048. GEICAM/2021-07
Financier: ARVINAS ESTROGEN RECEPTOR INC
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 27/01/2023 - 30/06/2024
IP: ISABEL BLANCAS LOPEZ-BARAJAS
Phase II study of trastuzumab deruxtecan in the first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer (MBC) considered resistant to trastuzumab + pertuzumab + taxane due to early relapse.
Funder: FUNDACION GRUPO ESPAÑOL DE INVESTIGACIÓN EN CANCER MAMA
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 10/08/2023 - 30/03/2029
IP: ISABEL BLANCAS LOPEZ-BARAJAS
Phase II study for advanced metaplastic breast cancer with PI3KCA/PTEN alteration treated with MEN1611 monotherapy or in combination with eribulin. –SABINA study
Financer: MEDICA SCIENTIA INNOVATION RESEARCH, SL
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 09/02/2023 - 31/12/2024
IP: ISABEL BLANCAS LOPEZ-BARAJAS
Preoperative window of opportunity study with giraredestrant (GDC-9545) or tamoxifen in premenopausal women with early-stage breast cancer (EBC) ER[+]/HER2[-] and Ki67=10%”. – The EMPRESS study
Financer: MEDICA SCIENTIA INNOVATION RESEARCH, SL
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 26/06/2023 - 30/09/2024
IP: ISABEL BLANCAS LOPEZ-BARAJAS
Preliminary efficacy study to evaluate the efficacy of treatments by controlling minimal residual disease with ctDNA in the population with RH-positive/HER2-negative early breast cancer. MIRADOR
Financer: MEDICA SCIENTIA INNOVATION RESEARCH, SL
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 03/04/2023 - 30/04/2028
IP: ISABEL BLANCAS LOPEZ-BARAJAS
Retrospective, observational, multicenter, real-life study of dostarlimab in patients with recurrent endometrial cancer with mismatch repair (MMR) deficiency or high microsatellite instability. DORA study
Funder: SPANISH OVARIAN CANCER RESEARCH GROUP
Type of test: OBSERVATIONAL STUDY WITH MEDICATION
Execution time: 08/02/2023 - 30/12/2023
IP: MARTA LEGEREN ALVAREZ
Observational, multicenter, international study to understand the effect of the COVID-19 pandemic on the treatment of patients with unresectable stage III non-small cell lung carcinoma (NSCLC)
Funder: ASTRAZENECA UK LTD
Type of test: COMMERCIAL POST AUTHORIZATION STUDY
Execution time: 26/01/2022 - 30/12/2022
IP: SILVIA SEQUERO LOPEZ
Evaluation of outcomes of patients with metastatic or locally advanced breast cancer treated with abemaciclib who participate in the Patient Support Program in Spain. 2019-9039 VERZENIOS
Financier: LILLY, SA
Type of test: OBSERVATIONAL STUDY WITH MEDICATION
Execution time: 12/08/2022 - 31/03/2024
IP: ISABEL BLANCAS LOPEZ-BARAJAS
Observational study to monitor the activity of patients with lung cancer and evaluate their functional status using mobile devices. MAGNIFYING-01
Financier: ROCHE FARMA, SA
Type of test: OBSERVATIONAL STUDY WITH MEDICATION
Execution time: 07/11/2022 - 31/05/2023
IP: SILVIA SEQUERO LOPEZ
Phase II clinical trial of the combination of palbociclib, trastuzumab, and endocrine therapy, in patients with previously treated HER2-positive locally advanced or metastatic breast cancer. PATRICIA II. GEICAM/2018-07
Funder: SOLTI
Type of test: INDEPENDENT CLINICAL TRIAL
Execution time: 24/02/2022 - 28/02/2025
IP: ISABEL BLANCAS LOPEZ-BARAJAS
Observational and multinational study to characterize the use and efficacy of abemaciclib in patients with metastatic breast cancer.
Financier: LILLY, SA
Type of test: OBSERVATIONAL STUDY WITH MEDICATION
Execution time: 23/09/2022 - 30/12/2023
IP: ISABEL BLANCAS LOPEZ-BARAJAS
EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer With an Increased Risk of Recurrence
Financier: LILLY, SA
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 08/12/2022 - 30/03/2025
IP: ISABEL BLANCAS LOPEZ-BARAJAS
Phase II clinical trial of AMG510 (SOTORASIB) in patients with unresectable stage III non-small cell lung cancer (NSCLC) with kras p.G12 mutation ineligible for treatment with chemoradiotherapy. MERIT-lung
Funder: GECP FOUNDATION
Type of test: INDEPENDENT CLINICAL TRIAL
Execution time: 15/02/2022 - 30/09/2027
IP: SILVIA SEQUERO LOPEZ
Phase II, open-label, multicenter trial to evaluate the efficacy and safety of nal-IRI in patients with HER2-negative breast cancer with progressive brain metastases
Financer: MEDICA SCIENTIA INNOVATION RESEARCH, SL
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 28/11/2022 - 30/04/2024
IP: ISABEL BLANCAS LOPEZ-BARAJAS
Multicenter, Open-label, Single Arm, Phase II Clinical Trial to Improve Sacituzumab Govitecan's Tolerance in Patients With Metastatic Triple-Negative Breast Cancer.
Financer: MEDICA SCIENTIA INNOVATION RESEARCH, SL
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 05/12/2022 - 31/12/2025
IP: ISABEL BLANCAS LOPEZ-BARAJAS
Randomized, Open-Label Phase 3 Trial of Datopotamab Deruxtecan (Dato-DXd) Compared to Investigator's Choice Chemotherapy in Patients With Inoperable Locally Recurrent or Metastatic Triple-Negative Breast Cancer Who Are Not Candidates for PD Inhibitor Therapy -1/PD-L1 in front line (TROPION-Breast02)
Funder: ASTRAZENECA FARMACEUTICA ESPAÑA SA
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 24/05/2022 - 30/12/2025
IP: ISABEL BLANCAS LOPEZ-BARAJAS
Phase II, randomized, open-label, 2-arm treatment study of abemaciclib in combination with endocrine therapy (letrozole or fulvestrant) with or without a short course of induction chemotherapy with paclitaxel as first-line treatment in patients with breast cancer HR positive/HER2 negative locally advanced and unresectable or metastatic with criteria for aggressive disease (ABIGAIL)
Financer: MEDICA SCIENTIA INNOVATION RESEARCH, SL
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 29/12/2021 - 30/06/2024
IP: ISABEL BLANCAS LOPEZ-BARAJAS
Phase 3, randomized, double-blind study to compare the efficacy and safety of niraparib versus placebo in participants with HER2-negative breast cancer with a BRCA mutation or triple-negative breast cancer, with molecular disease based on the presence of tumor DNA circulating after definitive therapy (ZEST).
Funder: GLAXOSMITHKLINE, SA
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 22/07/2022 - 30/06/2029
IP: ISABEL BLANCAS LOPEZ-BARAJAS
Phase III, double-blind, placebo-controlled, randomized, multicenter, international trial with Durvalumab plus Oleclumab and Durvalumab plus Monalizumab in patients with locally advanced (stage III) and unresectable non-small cell lung cancer (NSCLC) who have not progressed after a definitive concomitant platinum-based chemoradiotherapy (PACIFIC-9).
Funder: ASTRAZENECA FARMACEUTICA ESPAÑA SA
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 14/03/2022 - 30/10/2030
IP: SILVIA SEQUERO LOPEZ
Phase 1b/2a, Basket-type Study, to evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of the combination therapy of Tafasitamab, anti-CD19 monoclonal antibody, and Parsaclisib (PI3Kd Inhibitor), in Adult Patients with Non-Hodgkin's Lymphoma or Leukemia Chronic Lymphocytic Disease in Relapse or Refractory (topMIND)
Financer: INCYTE CORPORATION
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 28/06/2022 - 30/03/2023
IP: SILVIA SEQUERO LOPEZ
Phase II, randomized study to evaluate the incidence of discontinuation due to Diarrhea in the first 3 cycles of treatment in patients with HER2-positive (HER2+), Hormone Receptor-positive (HR+) Early Breast Cancer, treated with Neratinib plus Loperamide versus Neratinib with initial dose escalation plus Loperamide (as needed) versus Neratinib plus Loperamide plus Colesevelam. DIANER Study
Funder: FUNDACION GRUPO ESPAÑOL DE INVESTIGACIÓN EN CANCER MAMA
Type of test: INDEPENDENT CLINICAL TRIAL
Execution time: 15/07/2022 - 30/06/2030
IP: ISABEL BLANCAS LOPEZ-BARAJAS
Phase III, multicenter, randomized, open-label study to evaluate the efficacy and safety of adjuvant giredestrant compared to physician-selected adjuvant endocrine monotherapy in patients with estrogen receptor-positive, HER2-negative early breast cancer. LEAD
Financier: F. HOFFMANN-LA ROCHE LTD
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 25/02/2022 - 30/03/2034
IP: ISABEL BLANCAS LOPEZ-BARAJAS
Phase 1b/2, open-label, randomized, non-comparative study of nadunolimab in combination with gemcitabine and carboplatin in patients with advanced triple-negative breast cancer. “TRIFOUR Studio”
Financier: CANTARGIA AB
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 22/04/2022 - 30/08/2026
IP: ISABEL BLANCAS LOPEZ-BARAJAS
Observational study in patients with HR+ / HER2- metastatic breast cancer treated with Abemaciclib. Review of medical records
Financer: LILLY, SAU
Type of test: COMMERCIAL POST AUTHORIZATION STUDY
Execution time: 19/03/2021 - 01/04/2022
IP: ISABEL BLANCAS LOPEZ-BARAJAS
Encorafenib plus binimetinib in patients with real-life treated locally advanced, unresectable, or metastatic BRAFV600-mutated melanoma in Spain: a multicenter, retrospective, non-interventional study. BECARE
Funding: SPANISH MULTIDISCIPLINARY MELANOMA GROUP (GEM)
Type of test: REST OF OBSERVATIONAL STUDIES WITH MEDICINES
Execution time: 28/07/2021 - 30/06/2022
IP: SILVIA SEQUERO LOPEZ
Neoadjuvant and adjuvant ribociclib and endocrine therapy for clinically high-risk estrogen receptor-positive (ER+) and HER2-negative (HER2-) breast cancer. RIBOLARIS
Funder: SOLTI
Type of test: INDEPENDENT CLINICAL TRIAL
Execution time: 17/12/2021 - 28/02/2030
IP: ISABEL BLANCAS LOPEZ-BARAJAS
Study to evaluate the effect of metformin in the prevention of hyperglycemia in patients with HR positive/HER2 negative advanced breast cancer and PIK3ca mutation treated with alpelisib and endocrine therapy. Metallic studio.
Financer: MEDICA SCIENTIA INNOVATION RESEARCH, SL
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 23/03/2021 - 30/10/2022
IP: ISABEL BLANCAS LOPEZ-BARAJAS
Phase III, multicenter, randomized, open-label, controlled study of trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients with high-risk HER2-positive primary breast cancer presenting with residual invasive disease
Funder: DAIICHI-SANKYO, INC.
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 16/04/2021 - 30/03/2028
IP: ISABEL BLANCAS LOPEZ-BARAJAS
Phase III, multicenter, open-label study of ribociclib compared to palbociclib in patients with hormone receptor-positive/HER2-negative/HER2-enriched advanced breast cancer – HARMONIA trial
Funder: SOLTI
Type of test: INDEPENDENT CLINICAL TRIAL
Execution time: 18/11/2021 - 28/02/2028
IP: ISABEL BLANCAS LOPEZ-BARAJAS
Phase III, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of adjuvant treatment with atezolizumab or placebo and trastuzumab emtansine in HER2+-positive breast cancer at high risk of recurrence of
Financier: ROCHE FARMA, SA
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 25/01/2021 - 31/12/2031
IP: ISABEL BLANCAS LOPEZ-BARAJAS
Randomized phase III trial of trastuzumab + alpelisib +/- fulvestrant versus trastuzumab + chemotherapy in previously treated patients with HER2+ advanced breast cancer with PIK3CA mutation. “ALPHABET STUDIO”
Funder: FUNDACION GRUPO ESPAÑOL DE INVESTIGACIÓN EN CANCER MAMA
Type of test: INDEPENDENT CLINICAL TRIAL
Execution time: 14/09/2021 - 30/05/2026
IP: ISABEL BLANCAS LOPEZ-BARAJAS
EMBER-3: Phase 3, Randomized, Open-Label Study Comparing LY3484356 With Investigator's Choice Hormonal Therapy in Patients With Estrogen Receptor Expressing, Locally Advanced or Metastatic Breast Cancer Without Envelope
Financer: LILLY, SAU
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 31/05/2021 - 30/03/2023
IP: ISABEL BLANCAS LOPEZ-BARAJAS
eMonarcHER: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study Evaluating Abemaciclib With Standard Adjuvant Hormone Therapy In Participants With HR+, HER-2+, High-Risk, Nodal-Involved Breast Cancer Who
Financer: LILLY, SAU
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 01/09/2021 - 30/10/2031
IP: ISABEL BLANCAS LOPEZ-BARAJAS
Prediction of Sensitivity to Olaparib in Patients With Unresectable or Metastatic Locally Advanced HER2-Negative Breast Cancer With BRCA1, BRCA2, PALB2, RAD51C, or RAD51D Mutations or Low RAD51 Levels: RADIOLA ASSAY
Funder: SOLTI
Type of test: INDEPENDENT CLINICAL TRIAL
Execution time: 15/11/2021 - 28/02/2024
IP: ISABEL BLANCAS LOPEZ-BARAJAS
Chemotherapy-Free Strategy Based on Complete Pathologic Response With Subcutaneous Trastuzumab-Pertuzumab and T-DM1 in Early-Stage HER2-Positive Breast Cancer (PHERGAIN-2)
Financer: MEDICA SCIENTIA INNOVATION RESEARCH, SL
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 03/09/2021 - 30/12/2022
IP: ISABEL BLANCAS LOPEZ-BARAJAS
ATREZZO: Phase II clinical trial with two parallel cohorts in patients with negative estrogen receptors or non-luminal disease according to PAM50, Treatment with atezolizumab in combination with trastuzumab and vinorelbine in advanced breast cancer/
Funder: SOLTI
Type of test: INDEPENDENT CLINICAL TRIAL
Execution time: 13/01/2021 - 28/02/2026
IP: ISABEL BLANCAS LOPEZ-BARAJAS
Phase II clinical trial to evaluate the efficacy and safety of first-line treatment with atezolizumab in combination with paclitaxel and bevacizumab (Avastin®) in patients with advanced or metastatic triple-negative breast cancer. ATTRACTIVE
Financer: MEDICA SCIENTIA INNOVATION RESEARCH, SL
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 21/05/2021 - 30/03/2023
IP: ISABEL BLANCAS LOPEZ-BARAJAS